Epitalon Clinical Trials: What Was Actually Tested

Epitalon clinical trials are far thinner than the claims built on them. The long human studies people quote, where older adults were followed for years and fewer of them died, gave epithalamin, an extract of calf pineal glands, not synthetic epitalon. The synthetic peptide itself has reached people in about three published studies: one in an inherited eye disease and two short melatonin studies in night-shift workers. Nearly all of it comes from one research network, and no independent randomized trial has been published.

Epitalon and epithalon are two spellings of the same four-amino-acid peptide (Ala-Glu-Asp-Gly); Promise's catalog spells it epithalon. The cell and animal work lives in epitalon benefits, sorted by evidence tier.

Epithalamin vs epitalon: which substance was tested?

From the 1970s, Vladimir Khavinson's group in what is now St. Petersburg worked with epithalamin, a mix of peptides from the pineal gland (the small gland in the brain that makes melatonin). Epitalon, a single synthetic peptide modeled on the extract, came later; FDA's 2026 briefing dates its first synthesis to the late 1980s in one passage and, after a literature search, to 1999 in another.

In the briefing document it prepared for a July 2026 advisory meeting, FDA staff wrote that "epitalon and epithalamin are different substances," and noted that seven of the articles submitted to support epitalon described epithalamin. A result for one is not a result for the other.

The Khavinson study everyone cites

Most "epitalon extends life" claims trace to Khavinson and Morozov, 2003. It followed 266 older adults for six to eight years, giving two extracts, epithalamin and thymalin (from the thymus), during the first two to three years.

Compared with a control group, deaths were 1.6 to 1.8 times lower with epithalamin, 2.0 to 2.1 times lower with thymalin and 2.5 times lower with both.

Striking numbers, with limits to match. PubMed files the paper as a randomized trial, but the abstract doesn't say how people were placed in groups, and it describes no placebo and no blinding (keeping people unaware of who got what). And nobody in it received synthetic epitalon.

Epitalon clinical trials and human studies, side by side

The other long study came from Oleg Korkushko's team in Kiev, working with Khavinson: a 12-year randomized study of epithalamin in older heart patients on standard treatment, with 28% fewer deaths than controls. A 2011 report from the same team gives the group sizes, 39 treated and 40 controls. Small for a claim about death rates, and again, the extract.

The synthetic epitalon studies

FDA counted three published studies of synthetic epitalon in people.

The eye study. Khavinson and colleagues, 2002 gave epitalon by parabulbar injection (into the tissue around the eyeball) to people with retinitis pigmentosa, an inherited disease that damages the retina, and reported "a positive clinical effect in 90% of the cases." A 2025 Warsaw review (Araj and colleagues) describes 162 patients aged 18 to 72 and a comparison group on standard care. Epitalon held a U.S. orphan-drug designation for the disease from 2010 until it ended in 2016, per FDA's briefing; that is a development incentive, not a marketing authorization.

The melatonin studies. Ivko and colleagues enrolled 75 women aged 40 to 50, mostly night-shift workers. Of the 40 with low melatonin output, 20 got a saline spray under the tongue and 20 got epitalon, 0.5 mg a day for 20 days. A melatonin breakdown product in urine rose 1.7-fold on epitalon and stayed flat on placebo. FDA noted the paper didn't say whether it was blinded and didn't measure sleep. A companion report from the same group measured clock genes in blood cells.

What the side-effect data look like

None of these studies published an adverse-event table. This is the whole record:

"No side effects reported" is not the same as safe. These studies were small, short and not built to count harms. FDA's reviewers concluded there are "no clinical data to support the safety" of epitalon in humans, and found no data on how the body absorbs or clears it. Epitalon side effects covers the rest.

What FDA's reviewers and later studies said

FDA reviewed epitalon for insomnia after it was nominated for the 503A bulks list, a list of bulk ingredients that licensed compounding pharmacies may use. Staff found "a lack of evidence" of effectiveness and concluded the balance weighed against listing it. On July 24, 2026, the Pharmacy Compounding Advisory Committee voted 7 to 4 the other way, as STAT reported; the FDA meeting page has the recording. The vote is advice, not a decision.

As of September 22, 2026, the day this article was written, FDA had posted no decision on epitalon, and its 503A bulks-list page still read "current as of 05/14/2026." ClinicalTrials.gov, the U.S. study registry, listed no registered study of epitalon, epithalon or epithalamin, and PubMed held no randomized trial of the synthetic peptide from outside the St. Petersburg and Kiev network.

An April 2026 review in Frontiers in Aging (Mavrych and colleagues) says the unapproved peptides it covered, epitalon included, "lack long-term safety data and systematic validation."

What these studies can and cannot tell you

They show encouraging reports from one decades-long program, mostly with the extract. They can't show that synthetic epitalon extends life, lengthens telomeres in the body or improves sleep, because no study measured those things in people taking it. The two melatonin studies used noncompounded epitalon; the eye study's compounded status is unclear, and these reports establish neither a particular pharmacy product's performance nor a standard subcutaneous regimen; epitalon dosage explains how a prescriber handles that gap.

If the real interest is ageing and energy more broadly, NAD+ is studied at a different layer, cellular energy metabolism; NAD+ injections walks through its evidence.

How the gray market misreads the evidence

Sites selling epitalon without a prescription, often as vials labeled for laboratory use, make three leaps. They credit the extract's mortality data to the synthetic peptide. They turn a dish into a person: telomerase (an enzyme that rebuilds telomeres, the protective caps on chromosome ends) switching on in human fetal cells in a 2003 dish study becomes "lengthens your telomeres." In blood cells from 11 men exposed outside the body, telomeres rose in 5 samples and fell in 2. And they read "no side effects reported" as proof of safety.

A prescription filled by a licensed U.S. compounding pharmacy doesn't change the evidence. It adds a named prescriber who has read your history, a labeled product with a documented source, and someone to call.

Where epitalon stands if you are considering it

Epitalon has never had a U.S.-approved product, and the compounded formulation Promise will offer is not FDA-approved. Epithalon is coming soon to Promise — add me to the list. The advisory vote doesn't change that. A licensed provider may still prescribe a compounded formulation; that decision is between you and your doctor.

At Promise, a licensed provider reviews every request and weighs your history against evidence this thin. Not everyone qualifies.